Cite
HARVARD Citation
Fisher, B. et al. (2022). Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet. 10 (3), pp. 255-266. [Online].